Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

Objective: Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue diseases (CTD), with a negative impact on patients survival. Bosentan, a receptor antagonist of endothelin, has been proved effective for the treatment of PAH. The aim of this study was to evaluat...

Full description

Bibliographic Details
Main Authors:	M. Rizzo, S. Pontarollo, F. Tiso, R. Montisci, H. Marotta, F. Tona, S. Iliceto, F. Cozzi
Format:	Article
Language:	English
Published:	PAGEPress Publications 2011-09-01
Series:	Reumatismo
Online Access:	http://www.reumatismo.org/index.php/reuma/article/view/340

Similar Items

Review of bosentan in the management of pulmonary arterial hypertension
by: Eli Gabbay, et al.
Published: (2008-01-01)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
by: Kari E Roberts, et al.
Published: (2009-03-01)

Hidden hazards of Bosentan therapy in pulmonary hypertension
by: Sethi Swati, et al.
Published: (2008-01-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
by: Yuchen Wang, et al.
Published: (2019-07-01)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
by: Christopher J Valerio, et al.
Published: (2009-08-01)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
by: Ruxu You, et al.
Published: (2018-01-01)

Effect of bosentan therapy in persistent pulmonary hypertension of the newborn
by: Gunlawadee Maneenil, et al.
Published: (2018-02-01)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
by: Naomi Onda, et al.
Published: (2015-01-01)

Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01)

Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
by: Ahmad Amin, et al.
Published: (2015-01-01)

Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy
by: Nancy R Porhownik, et al.
Published: (2008-01-01)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
by: Karami H, et al.
Published: (2018-12-01)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
by: Pierangelo Chinello, et al.
Published: (2011-11-01)

Atrial flutter regression in HIV-associated pulmonary arterial hypertension after treatment with bosentan
by: Mario Francesco Damiani, et al.
Published: (2016-11-01)

Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
by: Nathan J. Verlinden, et al.
Published: (2020-12-01)

Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease
by: Giuseppe Valerio, et al.
Published: (2009-02-01)

Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension
by: Dulce Fontoura, et al.
Published: (2014-04-01)

Myocardial and anti‐inflammatory effects of chronic bosentan therapy in monocrotaline‐induced pulmonary hypertension
by: Dulce Fontoura, et al.
Published: (2014-04-01)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
by: Su-Gang Gong, et al.
Published: (2018-01-01)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
by: Carmine Dario Vizza, et al.
Published: (2017-09-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
by: Pawar Ravindra, et al.
Published: (2009-01-01)

Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension
by: Hans-Jürgen Seyfarth, et al.
Published: (2014-11-01)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
by: Raymond L. Benza, et al.
Published: (2018-01-01)

Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis
by: A V Volkov, et al.
Published: (2015-01-01)

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension
by: Shutan Liao, et al.
Published: (2019-08-01)

Bosentan for the treatment of portopulmonary hypertension
by: Tempe Deepak, et al.
Published: (2008-01-01)

An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease
by: Reda Ibrahim, et al.
Published: (2006-01-01)

Evaluation of effectiveness and safety of the first Russian-manufactured generic bosentan use in patients with pulmonary arterial hypertension
by: O A Arkhipova, et al.
Published: (2018-12-01)

PULMONARY ARTERIAL HYPERTENSION IN CONNECTIVE TISSUE DISEASES
by: A. V. Volkov
Published: (2015-03-01)

Pulmonary Arterial Hypertension in Connective Tissue Diseases
by: Shunji Yoshida
Published: (2011-01-01)

Cost-effectiveness of riociguat and bosentan for the treatment of chronic thromboembolic pulmonary hypertension
by: Ashaye, Ajibade O.
Published: (2018)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
by: Marzieh Nosrati, et al.
Published: (2020-01-01)

Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers.
by: Ivan Castellví, et al.
Published: (2020-01-01)

Effect of bosentan on the clinical status and cellular immunity of patients with idiopathic pulmonary hypertension
by: T V Martyniuk, et al.
Published: (2013-01-01)

Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
by: Mark J Schuuring, et al.
Published: (2010-08-01)

Cannot write session to /tmp/vufind_sessions/sess_sdhab0ea3bspmigbkbtphlrl51